Introduction:
In recent years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are being performed at an increasing frequency in many advanced centers of our country. The short-term quality of life (QoL) after CRS+HIPEC was investigated in the Turkish population. The purpose of our study was to investigate the QoL in patients operated for peritoneal carcinomatosis (PC).
Methods: Data collected retrospectively from 42 consecutive patients who had undergone CRS+HIPEC and 92 abdominal malignancy patients after an oncological surgery without CRS+HIPEC between 2012 and 2015 were selected in the study. The Turkish version of the European Organization for Research and Treatment of Cancer (EORTEC) questionnaire (QLQ-C30) was used at 6 months after surgery for QoL assessment. Statistical analysis was performed using one sample t-test and a p value <0.05 was accepted as statistically significant.
Results: A total of 42 CRS+HIPEC patients were analyzed, of which 30 (71.4 %) were females and 12 (28.5 %) were males. The median age was 52 years (range, 22-69). CRS+HIPEC were performed for colorectal carcinoma in 15 patients (35.7 %), ovarian cancer in 12 patients (28.5%), gastric cancer in 6 patients (14.2%), pseudomyxsoma peritonei in 3 patients (7.1%), sarcoma in 3 patients (7.1%), and mesenchymal tumor in 3 patients (7.1%). The median intraoperative peritoneal carcinomatosis index (PCI) score was 15 (range, 6-29), while the completeness of cytoreductive score (CCS) was 0 and 1. The median follow-up period for all patients was 12 months (range, 6-22). Functional and symptom scores were equal between CRS+HIPEC and without CRS+HIPEC cancer patients (p>0.05).
Conclusion:
The short-term QoL after CRS+HIPEC patients and without CRS+HIPEC oncologic patients are found to be similar in the Turkish population. 
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the QoL results of the PC patients with CRS+HIPEC compared to the oncologic patients operated only without CRS+HIPEC.
Methods
Data collected retrospectively from 42 PC patients who had undergone CRS+HIPEC in Çukurova University Medical Faculty, Departmen of Surgical Oncology Unit between December 2012 and May 2015 were analyzed. Preoperative evaluation was made with thoraco-abdominal computerized tomography (CT) and positron emission tomography (PET)-CT. Patients were chosen as candidates for CRS+HIPEC in a multidisciplinary oncology meeting aiming a complete cytoreduction. For comparison, 92 abdominal malignancy patients after oncological surgery without CRS+HIPEC were randomly selected in our oncology clinic. This study was approved by the Institutional Review Board of the Çukurova University (CUM 2015-48-28) and informed consent was obtained from each patient.
Intraoperative tumor spreading was evaluated by the PC index (PCI) (4) . Residual tumor presence after cytoreduction was reevaluated with residual completeness scoring (CCS) (5) . Mitomycin C and cisplatin were used according to the primary origin of the tumor. Chemotherapeutic drug selection and preparation were performed by the clinical oncology experts. After CRS, four intrabdominal drainage catheters were inserted into the abdomen, and HIPEC was administered for 60 minutes (range, 30-60).
The Turkish form of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, which was confirmed previously by Hoopman et al. (6) was selected for QoL (6) . All questionnaires were administered by clinical oncologists. Functional measurement (physical, role, cognitive, emotional, and social), symptom degree (fatigue, pain, dyspnea, loss of appetite, sleeping, diarrhea, constipation, nausea or vomiting, and financial problems), and global health status were measured in all patients. Scores ranged between 0 and 100 (7).
Statistical analyses were performed using the Statistical Package for Social Sciences program 15.0 for Windows (SPSS Inc.; Chicago, IL, USA). The mean QoL scores were calculated in both groups and compared by using one-sample t-test. P values <0.05 were considered statistically significant.
Results
Forty-two patients who underwent CRS+HIPEC were compared with 92 oncologic patients operated without CRS+HIPEC. Of the 42 patients with PC, 30 (71.4%) were females and 12 (28.5 %) were males. The median age was 52 years (range, 22-69). No significant difference was observed in the demographics of the two groups (Table 1) .
CRS+HIPEC were performed for colorectal carcinoma in 15 patients (35.7 %), ovarian cancer in 12 patients (28.5 %), gastric cancer in 6 patients (14.2 %), pseudomyxsoma peritonei in 3 patients (7.1 %), sarcoma in 3 patients (7.1 %), and mesenchymal tumor in 3 patients (7.1 %). The median intraoperative peritoneal carcinomatosis index (PCI) score was 15 (range, 6-29), while the completeness of cytoreductive score (CCS) was 0 and 1. The median follow-up period for all patients was 12 months (range, 6-22). Functional and symptom scores were equal between CRS+HIPEC and without CRS+HIPEC cancer patients (p>0.05). The Eastern Cooperative Oncology Group (ECOG) performance status of all patients was 0 or 1.
The without PC group included colorectal carcinoma in 44 patients (47.8 %), ovarian cancer in 30 patients (32.6 %), gastric carcinoma in 15 patients (16.3 %), and sarcomas in 3 patients (3.2%).
The median duration of operation for CRS+HIPEC was 480 minutes (range, 310-565) and that for without CRS+HIPEC group was 110 minutes (range, 80-160; p<0.001). The median PCI was 15 (range, 6-29). There were 39 patients with CCS 0 and 3 patients with CCS 1. The median admission in intensive care unit (ICU) was 1 day (range, 0-12). Median length of hospital stay was 13 days (range, 7-28).
The EORTC QLQ-C30 scores of patients after CRS+HIPEC compared to those without CRS+HIPEC are demonstrated in Table 2 . There were no differences between the groups of EORTC QLQ-C30 scores.
Discussion
CRS+HIPEC enhanced survival of patients with peritoneal dissemination of cancer (1-3). Despite improved survival and admissible morbidity and mortality of the surgery, QoL for the patients undergoing CRS+HIPEC is still controversial. Despite many articles that İstanbul Med J 2017; 18: X X (8) evaluated the QoL of patients who underwent CRS combined with HIPEC and found that QoL is associated with an increased morbidity and mortality according to the difficulty of surgery. In contrast, in the study by Alves et al. (9), EORTC QLQ C-30 questionnaire was applied to PC patients who had undergone CRS+HIPEC, and an improvement was noted in the QoL at 1 year following the procedure. Furthermore, Tan et al. (10) compared CRS+HIPEC patients with their cancerfree patients. In addition, cognitive functioning scores and fatigue scores were better in the CRS+HIPEC patients.
In the present study, the Turkish version of EORTC QLQ C-30 was evaluated between PC patients with CRS +HIPEC and patients without CRS+HIPEC at 6 months after surgery, and no significant difference was found between two groups. However, our study has some limitations. The first is the retrospective design. Lack of the patients' basic QoL scores for reference values after CRS+HIPEC is the second limitation. The third limitation is the variety of primary cancer origins. Compared to the population of oncology patients operated without CRS+HIPEC in our center, those who underwent CRS+HIPEC had similar scores in global health, physical functioning, emotional functioning, and social functioning.
Developing hospital care, advances in ICU for postoperative patient care, and a significant increase in the numbers of specialized oncology units in private sector as well as in the state hospitals can be the reason of no difference of QoL. However, successful tumor-free surgery, lack of serious morbidity, adequate enteral nutrition, achievement of longer disease-free survival, and rapid return to normalcy of the oncology patients are important factors affecting QoL. This is likely due to the fact that many patients after cancer surgery in Turkey start on chemotherapy, and the rapid return to their normal economic, social, and physical lives can be explained by the improved scores in both the CRS+HIPEC and without CRS+HIPEC groups.
Conclusion
Short-term QoL after CRS+HIPEC and oncology patients operated without CRS+HIPEC seems to be equal in our Turkish population.
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